EIGR ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of January 9, 2023 in the Class Action Filed on Behalf of Eiger BioPharmaceuticals, Inc. Shareholders

<br /> EIGR ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of January 9, 2023 in the Class Action Filed on Behalf of Eiger BioPharmaceuticals, Inc. Shareholders<br />

PR Newswire



NEW YORK


,


Nov. 29, 2022


/PRNewswire/ — The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) alleging that the Company violated federal securities laws.

Class Period:

March 10, 2021

to

October 4, 2022


Lead Plaintiff Deadline:


January 9, 2023



No obligation or cost to you.


Learn more about your recoverable losses in EIGR:


Eiger BioPharmaceuticals Class Action Submission Form



Eiger BioPharmaceuticals, Inc. NEWS – EIGR NEWS


CLASS ACTION CASE DETAILS:

The filed complaint alleges that Eiger BioPharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) defendants overstated Eiger’s clinical and regulatory drug development expertise; (ii) defendants failed to properly assess, and/or ignored issues with, the design of the TOGETHER study and its ability to support the Emergency Use Authorization (“EUA”) for the Company’s product candidate, peginterferon lambda ; (iii) there were issues with the conduct of the TOGETHER study and/or the TOGETHER study was not properly designed for the peginterferon lambda EUA in the current context of the pandemic; (iv) as a result, the U.S. Food and Drug Administration was unlikely to approve the submission of a peginterferon lambda EUA; (v) as a result of all the foregoing, peginterferon lambda’s regulatory and commercial prospects for the treatment of COVID-19 were overstated; and (vi) as a result, the Company’s public statements were materially false and misleading at all relevant times.


WHAT THIS MEANS TO YOU AS A SHAREHOLDER:

If you have suffered a loss in Eiger you have until


January 9, 2023


to petition the court for lead plaintiff status. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.


NO COST TO YOU:

If you purchased Eiger securities during the relevant period, you may be entitled to compensation without payment of any out-of-pocket fees.


HOW TO PROTECT YOUR FINANCIAL INTERESTS:

For additional information about the EIGR lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click this link:

Eiger BioPharmaceuticals Class Action Submission Form



.


ABOUT KLEIN LAW FIRM


J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. The Klein Law Firm is a boutique litigation firm with experience in a wide range of areas including securities law, corporate finance and commercial litigation. Since 2011, our experienced attorneys have achieved superior results for our clients with a personalized focus. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

J. Klein, Esq.

535 Fifth Avenue

4th Floor


New York City

, NY 10017


[email protected]


Telephone: (212) 616-4899


www.kleinstocklaw.com

Cision
View original content:

https://www.prnewswire.com/news-releases/eigr-alert-the-klein-law-firm-announces-a-lead-plaintiff-deadline-of-january-9-2023-in-the-class-action-filed-on-behalf-of-eiger-biopharmaceuticals-inc-shareholders-301688453.html

SOURCE The Klein Law Firm